ClinicalTrials.gg
Active, not recruitingNCT05647122EGRETUpdated Sep 25, 2026

First in Human Study of AZD9592 in Solid Tumors

A Phase 1 interventional study of AZD9592 and Osimertinib in Advanced Solid Tumours, Carcinoma Non-small Cell Lung and Head and Neck Neoplasms, sponsored by AstraZeneca. Active, not recruiting at 46 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Primary conditionNeoplasms(registry's first term: Carcinoma, Non-Small-Cell Lung)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Carcinoma, Non-Small-Cell Lung, so we do not take that as its main condition. It is compared within Neoplasms.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

How we know · 15 judgments

Updated Sep 25, 2026Primary completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.

02

Conditions studied

  • Advanced Solid Tumours
  • Carcinoma Non-small Cell Lung
  • Head and Neck Neoplasms
  • Colorectal Neoplasms

Browse trials for

Keywords

  • Cancer
  • First in Human
  • Antibody Drug Conjugate
  • Solid Tumour
  • Phase I
03

In context

Neoplasms Many cancers

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 190 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.

Compared within Neoplasms: the study is open to many cancers; the registry's first condition term is Carcinoma, Non-Small-Cell Lung. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 years
  • (ECOG) Performance Status: 0-1
  • ≥ 12 weeks
  • per v1.1
  • Adequate organ and marrow function as defined in the protocol

Additional Inclusion Criteria for Module 1:

  • or cytologically confirmed or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC.

Additional Inclusion Criteria for Module 2:

  • Histologically or cytologically confirmed metastatic NSCLC EGFRmut.

Additional Inclusion Criteria for Module 3:

  • Histologically or cytologically confirmed metastatic CRC.

Key Exclusion Criteria:

  • History of (non-infectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Spinal cord compression or a history of .
  • Active infection including tuberculosis and , or
  • unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 2 weeks prior to start of study treatment.
  • Participants with cardiac comorbidities as defined in the study protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Module 1 AZD9592 Monotherapy

    Module 1 has two parts: Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592. Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 as monotherapy in select solid tumors

    Drug: AZD9592

  • Experimental
    Module 2 AZD9592 Combination with Osimertinib

    Module 2 has two parts: Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with Osimertinib. Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with Osimertinib in NSCLC EGFRm

    Drug: AZD9592 · Drug: Osimertinib

  • Experimental
    Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin

    Module 3 has two parts: Part A aims to determine the safety, tolerability and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC)

    Drug: AZD9592 · Drug: 5-Fluorouracil (5-FU) · Drug: Leucovorin · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Number of patients with adverse events by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of AZD9592

  2. Incidence of Serious Adverse Events (SAEs)

    Number of patients with serious adverse events by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of AZD9592

  3. Incidence of dose-limiting toxicities (DLT) as defined in the protocol

    Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol

    Time frame: From time of first dose of AZD9592 to end of DLT period (approximately 21 days)

  4. Incidence of baseline laboratory finding, ECG and vital signs changes

    measured by laboratory and vital sign variables over time including change from baseline

    Time frame: From time of Informed Consent to 30 days post last dose of AZD9592

  5. Proportion of patients with radiological response (ORR)

    Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1 (for patients in the dose expansion cohorts, only)

    Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)

    Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  2. Duration of Response (DoR)

    The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression

    Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  3. Disease Control Rate (DCR) at 12 weeks

    The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1) for \>=11 weeks from first dose

    Time frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (for each patient this is expected to be measured at 12 weeks)

  4. Progression free Survival (PFS)

    The time from first dose until RECIST 1.1 defined disease progression or death due to any cause

    Time frame: From date of first dose of AZD9592 up until date of progression or death due to any cause (approximately 2 years)

  5. Overall Survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause.

    Time frame: From date of first dose of AZD9592 up until the date of death due to any cause (approximately 2 years)

  6. Pharmacokinetics of AZD9592: Plasma PK concentrations

    Measurement of plasma concentrations of AZD9592, total antibody and total unconjugated warhead

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

  7. Pharmacokinetics of AZD9592: Area under the concentration time curve (AUC)

    Measurement of PK parameters: Area under the concentration time curve (AUC)

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

  8. Pharmacokinetics of AZD9592: Maximum plasma concentration of the study drug (C-max)

    Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

  9. Pharmacokinetics of AZD9592: Time to maximum plasma concentration of the study drug (T-max)

    Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

  10. Pharmacokinetics of AZD9592: Clearance

    Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

  11. Pharmacokinetics of AZD9592: Half-life

    Measurement of PK parameters: Terminal elimination half-life (t 1/2)

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

  12. Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA)

    Evaluating the number and percentage of patients who develop Anti-drug antibody (ADA) during treatment

    Time frame: From date of first dose of AZD9592 up until 30 days post last dose

07

Study locations

46 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    North Haven, Connecticut 06473, United States
  • Research Site
    Washington D.C., District of Columbia 20016, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Milford, Massachusetts 01757, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
  • Research Site
    Beijing, 100142, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Wuhan, 430048, China
  • Research Site
    Marseille, 13385, France
  • Research Site
    Rennes, 35000, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jun 2026, 41 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 41 months is close to that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2028 → Jun 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Dec 12, 2022
StartActual
Dec 21, 2022
Primary completionActual
Jun 16, 2026was Aug 2028
CompletionEst.
Aug 3, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 3, 2028→Jun 16, 2026 (actual)
Sep 25, 2026
Enrollment
167→190
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Aug 3, 2028→Jun 16, 2026 (now actual)
    Enrollment 167→190
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05647122
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Dec 21, 2022
Primary completion
Jun 16, 2026
Completion
Aug 3, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Charu Aggarwal, MD, MPH
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilatamig samrotecan

Start the discussion